TAXIS is developing drugs to reduce and possibly eliminate the threat to societal health of antibiotic resistant bacterial pathogens. Our science is focused on the disruption of the foundation of bacterial cell wall architecture to address elemental forms of drug resistance. Our proprietary drug development platform has yielded multiple novel drug candidates targeting both Gram-positive and Gram-negative multidrug resistant (MDR) pathogens. TXA709, an oral anti-MRSA drug candidate currently in Phase I clinical trials, targets FtsZ: an essential bacterial cytoskeletal protein (BCP). We have recently identified FtsZ-targeting Gram-negative agents and have identified another novel BCP target, MreB, both of which are in Hit-to-Lead stage. Our efflux pump inhibitor platform has yielded multiple adjuvant drug candidates that resurrect activity of 28 generic antibiotics and display durable, validated in vivo efficacy. No drugs on the market or in development target FtsZ, MreB or EPIs.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):